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1356Objectives: Transapical aortic valve implantation significantly reduces operative risk in elderly patients with
aortic valve stenosis and comorbidities. However, it is unknown whether this procedure is feasible in patients
with advanced heart failure.
Methods: Between April 2008 and July 2010, 258 patients underwent transapical aortic valve implantation.
Twenty-one patients had advanced heart failure with decompensation and a left ventricular ejection fraction
of 10% to 25%. The mean age of these patients was 74  11 years (range, 36-88 years). The mean left ventric-
ular ejection fraction was 20% 5% (range, 10%-25%). Mean logistic EuroSCORE was 66% 21% (range,
27%-97%) and mean Society of Thoracic Surgeons score 33%  25% (range, 4%-90%). Nine patients were
operated on using femorofemoral cardiopulmonary bypass and 12 without.
Results: Technical success of the procedure was 100% with no conversion to conventional surgery. The mean
time of cardiopulmonary bypass was 27 25 minutes (range, 6-81 minutes). Postoperatively, the left ventricular
ejection fraction increased to 38%  12% (range, 20%-60%). There were no postoperative neurologic com-
plications. A new pacemaker implantation was needed in 2 (10%) patients. The 30-day mortality was 4.8%.
Survival at 1, 3, 12, and 24 months was 95%, 81%, 76%, and 62%, respectively.
Conclusions: Transapical aortic valve implantation can be performed safely in patients with decompensated
heart failure or even in the presence of cardiogenic shock. (J Thorac Cardiovasc Surg 2012;143:1356-63)Conventional aortic valve replacement has been the ‘‘gold
standard’’ in the treatment of severe aortic valve stenosis
with excellent confirmed results over decades.1 However,
it is still a challenge in patients with advanced heart failure,
in whom survival is markedly reduced regardless of the type
of treatment.2,3 If acute cardiac decompensation or
cardiogenic shock is present, percutaneous valvuloplasty
as a bridge to aortic valve replacement4 ormechanical circu-
latory support and aortic valve replacement5 have been re-
ported as treatment options. The prognosis of aortic valve
stenosis is grave in patients who are not candidates for aortic
valve replacement, regardless of the therapeutic strategy.6
Transcatheter aortic valve implantation (with a transfe-
moral, transapical, or transaxillary approach) has been in-
troduced as an alternative to conventional aortic valve
replacement for elderly and polymorbid patients.7-10
Transapical aortic valve implantation can be applied even
in the presence of severe peripheral arterial disease, and
there is the advantage of direct, short, and antegrade
access to the aortic valve with possibly more preciseeutsches Herzzentrum Berlin, Berlin, Germany.
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Excellent early results can be achieved if left ventricular
performance is preserved. Presently, the reported 30-day
mortality is between 5% and 12% in centers experienced
in the procedure.11-16 A first report with a follow-up of up
to 3 years in a limited number of patients and optimistic re-
sults has recently been published.17 A review of several ad-
vantages and serious complications of the transcatheter
procedure in comparison with conventional surgery has re-
cently appeared.18
Up to now, it is unclear whether transapical aortic valve
implantation is a feasible option in the presence of advanced
heart failure or cardiogenic shock. Here, we report our
experience with transapical aortic valve implantation in
21 patients with poor left ventricular performance.PATIENTS AND METHODS
Patients
Between April 2008 and July 2010, a total of 258 consecutive patients
with severe aortic valve stenosis underwent transapical aortic valve implan-
tation. In this retrospective study, patients were divided into 2 groups ac-
cording to their preoperative left ventricular ejection fraction (LVEF).
Group I (mean age, 74  11 years; range, 36-88 years) consisted of 21 pa-
tients with an LVEF of 10% to 25% measured by preoperative transtho-
racic or transesophageal echocardiography. Group II (mean age, 80  8
years; range, 37-99 years) served as controls and consisted of 237 patients
with an LVEF of more than 25%. The baseline characteristics of groups I
and II are given in Table 1.
There were 12 (57%) men and 9 (43%) women in group I, the group
with poor left ventricular performance. The mean logistic EuroSCORE
for this group was 65.7%  20.6%, with a range from 26.9% to 96.7%.gery c June 2012
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
LVEF ¼ left ventricular ejection fraction
Unbehaun et al Acquired Cardiovascular Disease
A
C
DThe mean Society of Thoracic Surgeons score for group I was 33.3% 
25.6%, with a range from 3.8% to 89.5%. All these patients were highly
symptomatic and referred for at least urgent surgery on the aortic valve. Ten
(49%) of them had cardiogenic shock, needed intensive care unit treat-
ment, and were dependent on catecholamine support at least after induction
of anesthesia. Six (29%) patients were receiving continuous epinephrine
therapy with a dosage of 0.04 to 0.29 mg $ kg1 $min1. Two (10%) patients
needed continuous treatment with dobutamine (4.2 mg $ kg1 $ min1 and
4.8 mg $ kg1 $ min1) and phosphodiesterase III inhibitor (milrinone
0.19 mg $ kg1 $min1 and 0.22 mg $ kg1 $min1). One patient was receiv-
ing intra-aortic balloon counterpulsation, and in 2 others with cardiogenic
shock the plan was to implant an intra-aortic balloon pump during the pro-
cedure. Therewere 6 (29%) patients with new-onset acute renal failure ow-
ing to circulatory depression and 4 of them required hemodialysis. Seven
(33%) patients showed metabolic acidosis and 1 (5%) needed respirator
support.
The preoperative characteristics of the control group II are given in Table
1. In general, patients were considered for transapical aortic valve implan-
tation if the logistic EuroSCOREwas at least 20% or if the Society of Tho-
racic Surgeons scorewas 10% or higher. If the risk score values were lower,
the patients were considered for the procedure only if there were specific
pathologic conditions with high risk for conventional aortic valve surgery
(eg, porcelain aorta). The only exclusion criteria were active valve endocar-
ditis, an aortic valve annulus greater than 24 mm, and bicuspid aortic valve
morphology. According to our institutional ‘‘no exclusion policy,’’ patients
with a very high risk profile, poor left ventricular performance, or even pro-
found shock were also considered for this type of treatment.15 Therefore,
there are some patients in group I in whom the intervention on the aortic
valvewas considered an ultima-ratio attempt. All patients or their represen-
tatives gave informed consent. The mean follow-up was 10.4 7.9 months
(range, 1-27 months). No patients were lost to follow-up.Methods
The preoperative examinations included clinical and blood examina-
tions, electrocardiogram, chest radiograph, coronary angiography, trans-
thoracic echocardiography, computed tomography of the chest (Figure 1)
and pelvis, and ultrasound examinations (Doppler) of the peripheral and ca-
rotid arteries. In patients with hemodynamic instability, we waived com-
puted tomography. Physical examination, neurologic clinical findings,
transthoracic echocardiography, and the battery of blood examinations
were repeated during the first week postoperatively or as long as the patient
was in the hospital. Postoperative computed tomographic scans of the chest
and the cranium were performed as a standard protocol in the first 200 pa-
tients but only exceptionally in the last 58 patients.
All procedures were performed in a hybrid operating roomwith a mono-
plane angiography system (Siemens Artis zee; Siemens AG, Munich,
Germany). All valve implantations were performed by the same team con-
sisting of 5 surgeons, 2 cardiologists, and 2 anesthesiologists with expertise
in echocardiography dedicated to this program. A perfusionist and a heart–
lung machine were always present in the operating room and at least in
a stand-bymode. In patientswith advanced heart failure and for specific rea-
sons (eg, short distance of the coronary ostia to the annulus), the connecting
tubes for the heart–lungmachinewere placed on the table and ready to con-
nect instantly. The elective use of cardiopulmonary bypass (CPB) was con-
sidered in patients with cardiogenic shock or poor left ventricular function
(LVEF, 10%–20%). The femoral vein and the common femoral artery (orThe Journal of Thoracic and Carthe axillary artery) were cannulated. It was decided preoperatively in these
specific cases whether valve implantation had to be performed under a short
duration of CPB or without starting up the heart–lung machine. Immedi-
ately before the procedure, the whole team analyzed the diagnostic workup
and discussed possible technical difficulties and complications and the way
to prevent them, as well as the use of the heart–lung machine. Elective cor-
onary artery stent implantationwas considered in patients with concomitant
coronary artery disease.Only themost relevant coronary artery stenosis was
considered to be a target for stent implantation.15 Concomitant atrioventric-
ular valve disease was not treated simultaneously (except with grade IV
regurgitation of the tricuspid valve).
All procedures were performed with the patient under general anesthe-
sia. The procedure was performed through a left anterior minithoracotomy,
usually in the sixth or seventh intercostal space. The left side of the chest
was slightly elevatedwhile the patient lay in the supine position.Valve prep-
aration was started at the time of puncture of the femoral vessels and the in-
cision on the chest. The principal surgical technique that has been described
in detail by Walther and associates19 was applied in the first 20 patients. In
all further cases, the valve was deployed according to our modification of
the technique (‘‘Berlin addition’’) that has been described in detail else-
where.20 Balloon-expandable transcatheter stent–prosthetic xenograft
valves of 23- or 26-mmdiameterwith their delivering system (bothEdwards
SAPIEN THV; Edwards Lifesciences, Irvine, Calif) were used in all pa-
tients. The size of the valve used was determined according to the diameter
of the native aortic valve annulus as measured by intraoperative transeso-
phageal echocardiography. We chose a valve size of 23 mm for aortic valve
annuli smaller than 21 mm and a 26-mm prosthesis for annulus diameter of
21 mm and greater. The procedure was monitored by fluoroscopy, angiog-
raphy, and intraoperative transesophageal echocardiography.
Statistical Analysis
Continuous variables are expressed as mean  standard deviation and
maximal and minimal absolute numbers. Statistical analyses were carried
out with the Student t test, the c2 test, or the Fisher exact test. A Kaplan-
Meier survival function was calculated for each group. A Gehan test was
used to analyze differences between 2 survival functions. A univariate lo-
gistic regression analysis was performed. The data were evaluated by SPSS
software version 17.0 for Windows (SPSS, Inc, Chicago, Ill).
RESULTS
Early Survival
The 30-day survival for the whole group of 258 patients
was 95.3% (overall early mortality, 4.7%; 12 patients
died). The 30-day survival for group I (21 patients with an
LVEF of 10% to 25%) was 95.3% (early mortality,
4.8%; 1 patient died). In comparison, the 30-day survival
for group II (237 patients with an LVEF above 25%) was
95.4% (early mortality, 4.6%; 11 patients died). The cause
of early death in group I was acute myocardial failure on the
day of the operation in a patient with cardiogenic shock,
acute renal failure, and preoperative adrenaline therapy.
Besides an uneventful valve implantation, a myocardial re-
covery failed to appear even after intra-aortic balloon coun-
terpulsation had been established. The causes of early
deaths in group II were septicemia in 1 patient with preop-
erative methycillin-resistant Staphylococcus aureus, acute
myocardial failure in 2, multiorgan failure in 4, basilar
vein thrombosis in 1, abdominal complications in 2, and
leg ischemia related to severe peripheral arterial disease
and type II heparin-induced thrombocytopenia in 1.diovascular Surgery c Volume 143, Number 6 1357
TABLE 1. Preoperative characteristics in 258 patients
Parameter
Group I (n ¼ 21)
LVEF  25%
Group II (n ¼ 237)
LVEF>25% P value
Age, year 74.2  10.8 79.8  7.9 .003
Male n ¼ 12 57% n ¼ 67 28% .011
Body mass index, kg/m2 26.2  5.1 26.9  5.5 .592
Logistic EuroSCORE,% 65.7  20.6 36.5  17.1 .001
STS score,% 33.3  25.6 18.5  13.6 .001
NT-proBNP, pg/mL 17103  17886 4387  6562 .001
NYHA class IV n ¼ 16 76% n ¼ 63 27% .001
Cardiogenic shock n ¼ 10 48% n ¼ 6 3% .001
Cerebral ischemic lesion(s) n ¼ 10 48% n ¼ 66 28% .078
Diabetes mellitus n ¼ 8 38% n ¼ 52 22% .107
Coronary artery disease n ¼ 13 62% n ¼ 136 57% .819
Serum creatinine, mg/dL 1.6  0.7 1.2  0.7 .034
COPD n ¼ 8 38% n ¼ 105 44% .651
FEV1, L 1.6  0.6 1.5  0.5 .567
Peripheral arterial disease n ¼ 13 62% n ¼ 162 68% .627
Systolic PAP  50 mm Hg n ¼ 8 38% n ¼ 92 39% 1.000
Porcelain aorta n ¼ 2 10% n ¼ 14 6% .627
Atrial fibrillation n ¼ 5 24% n ¼ 79 33% .470
Pacemaker or ICD n ¼ 3 14% n ¼ 23 10% .454
Previous CABG n ¼ 5 24% n ¼ 37 16% .354
Previous AVR n ¼ 1 5% n ¼ 13 16% 1.000
Previous MVR n ¼ 1 5% n ¼ 6 3% .452
Mitral regurgitation>grade 2 n ¼ 3 14% n ¼ 14 6% .150
Tricuspid regurgitation>grade 2 n ¼ 2 10% n ¼ 8 3% .191
LVEF,% 20.4  5.3 52.9  10.5 —
LVEDD, mm 57.3  8.6 48.3  6.9 .001
Mean aortic valve area, cm2 0.8  0.3 0.6  0.1 .006
Mean dP, mm Hg (TTE) 33.1  13.5 50.2  13.8 .001
Aortic regurgitation>grade 2 n ¼ 1 5% n ¼ 16 7% 1.000
Annulus, mm 22.3  1.0 22.3  1.3 .950
Boldface indicates P<.05. LVEF, Left ventricular ejection fraction; STS, The Society of Thoracic Surgeons; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New
York Heart Association; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; PAP, pulmonary artery pressure; ICD, implantable cardiac
defibrillator;CABG, coronary artery bypass grafting; AVR, aortic valve replacement;MVR,mitral valve repair or replacement; LVEDD, left ventricular end-diastolic diameter; dP,
transvalvular gradient; TTE, transthoracic echocardiography.
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We chose a 23-mm valve in 4 (19%) patients and
a 26-mm prosthesis in 17 (81%) patients. During the
same procedure 1 (5%) patient received a second valve im-
planted within the first valve (‘‘valve in valve’’) owing to
relevant transvalvular regurgitation. There was no conver-
sion to conventional surgery. Concomitant coronary artery
disease was treated during the same procedure by elective
stent implantation into the right coronary artery in 3
(14%) patients and by stent implantation into a narrowed
vein graft to the circumflex artery in 1 (5%) patient. The
primary result of coronary intervention was good in all pa-
tients. One patient received off-pump bypass grafting of the
left internal thoracic artery to the left anterior descending
artery via a median sternotomy. Transapical aortic valve im-
plantation was performed in this case via an additional 1-cm
left subcostal incision that was further used to place a tube
into the pleural cavity. Elective femorofemoral CPB was1358 The Journal of Thoracic and Cardiovascular Surapplied in 9 (43%) patients with severe cardiogenic shock
and/or poor left ventricular function (LVEF, 10%-20%).
The mean duration of CPB was 27.4  24.6 minutes, with
a range from 6 to 81 minutes (Figure 2). In a further 2
(10%) patients, cannulas were placed and connected with-
out starting up the heart–lung machine. In 1 of them, who
had chronic Leriche syndrome, the left axillary artery was
exposed and cannulated. There was neither unexpected
nor emergency use of the heart–lung machine.
At the end of the procedure, 15 (71%) patients were re-
ceiving catecholamine therapy. The mean dosage of epi-
nephrine was 0.15  0.11 mg $ kg1 $ min1, with a range
from 0.05 to 0.36 mg $ kg1 $ min1.
The mean fluoroscopy time for the whole group was 11.7
 5.7 minutes (range, 5.3-24.5 minutes). The mean dose
area product for the whole group was 7213  2407 mGy
m2 (range, 2175-10,904 mGy m2). The mean dosage of
the contrast agent iopromide (ULTRAVIST-370; Bayergery c June 2012
FIGURE 1. Computed tomographic scans of the chest before (left side) and 1 week after transapical aortic valve implantation (right side) in a 75-year-old
male patient with advanced biventricular heart failure, porcelain aorta, severe tricuspid valve regurgitation, previous cardiodefibrillator implantation (ICD),
and thrombus formation in the giant left atrium. The patient underwent replacement of the aortic valve and aortic root (28-mm homograft) owing to aortic
valve stenosis, endocarditis, and annular abscess formation 13 years before. A biological mitral valve replacement (33-mmHancock) was performed 2 years
previously. Transapical aortic ‘‘valve-in-valve’’ implantation was performed under cardiopulmonary bypass (CPB) of short duration (13 minutes) after fem-
orofemoral cannulation. Left ventricular ejection fraction (LVEF) increased from 20% preoperatively to 40% postoperatively. Functional New York Heart
Association class improved from stage IV preoperatively to stage II 8 months after transapical aortic valve implantation. PE, Pleural effusion; RV, right
ventricle; RA, right atrium with ICD lead; Ao, aorta with circumferential calcification of the implanted homograft; LV, enlarged left ventricle; LA, giant
left atrium with adherent thrombus (Th); MV, 33-mm Hancock prosthesis; AV, 26-mm SAPIEN prosthesis.
Unbehaun et al Acquired Cardiovascular Disease
A
C
DAG, Leverkusen, Germany) for aortic valve implantation in
the whole group was 92  33 mL (range, 38-139 mL).
Intraoperative Echocardiographic Data in Group I
Aortic valve stenosis was eliminated in all patients. The
mean transvalvular gradient reduced from 33.1  13.5
mm Hg (range, 10-57 mmHg) in preoperative transthoracic
echocardiography to 4.6  1.8 mm Hg (range, 1.5-7.8 mm
Hg) in postoperative transesophageal echocardiography. At
the end of the procedure, there was no aortic valve regurgi-
tation in 11 (52%) patients, only trace or mild regurgitation
(grade I) in 9 (43%) patients, and mild regurgitation
(grade I-II) in 1 (5%) patient.
In-Hospital Follow-up in Group I
The mean in-hospital stay at our institution was 17.5 
12.3 days, with a range from 5 days to 41 days. All survivorsThe Journal of Thoracic and Carof this period were transferred to an associated general hos-
pital before discharge home or to a rehabilitation clinic. Af-
ter passing the 30-day interval, 2 patients died in our
hospital on day 33 and day 49 owing to septicemia and
pneumonia. The mean stay on the intensive care unit was
5.9  8.2 days (range, 1-33 days). After that, 10 (48%) pa-
tients were further treated on an intermediate care unit for
another 2 to 38 days.
Theweaning from catecholamine support was uneventful
in all 15 patients and weaning from intra-aortic balloon
counterpulsation was uneventful in all 3 patients. Thewean-
ing from the respirator was prolonged (ie, lasted>24 hours)
in 4 (19%) patients. In another 4 (19%) patients, reintuba-
tion followed by percutaneous tracheostomy was performed
owing to general weakness or ongoing pneumonia. There
was no new-onset acute renal failure requiring hemodialysis
during the postoperative course. There were also no newdiovascular Surgery c Volume 143, Number 6 1359
FIGURE 2. A,Valve deployment according to the ‘‘Berlin-addition technique’’20 under short duration of cardiopulmonary bypass (black arrow, venous
cannula). B, Angiographic results after transapical aortic valve implantation. The patient was preoperatively in cardiogenic shock, in acute renal failure
with severe metabolic acidosis, and dependent on epinephrine and intra-aortic balloon counterpulsation.
Acquired Cardiovascular Disease Unbehaun et al
A
C
Dclinical signs of stroke after the procedure. A permanent
pacemaker was implanted in 2 (10%) patients on days 1
and day 20, respectively, after transapical aortic valve im-
plantation. There was 1 (5%) patient with severe peripheral
arterial disease in whom leg ischemia developed; a percuta-
neous angioplasty of the right anterior tibial artery was per-
formed 1 week after transapical aortic valve implantation.
In 1 (5%) patient with decompensated heart failure, ana-
sarca, and ascites, abdominal puncture to drain ascites
was repeatedly performed. Another (5%) patient with car-
diogenic shock, acute renal failure, anasarca, and recurrent
pleural effusion had hemothorax of the right side about 1
month after transapical aortic valve implantation for un-
known reasons. The hematoma was uneventfully removed
through a right-anterior minithoracotomy.
A significant improvement in left ventricular perfor-
mance was observed by transthoracic echocardiography
within 2 weeks after aortic valve implantation (Figure 3).
LVEF increased significantly (P< .001) from 20.4% 
5.3% (range, 10%-25%) preoperatively to 38.4% 
11.5% (range, 20%-60%) postoperatively. Left ventricularFIGURE 3. Left ventricular ejection fraction (LVEF) and end-diastolic diame
 25%) before and after transapical aortic valve implantation (TAVI). LVEF
38.4%  11.5%. LVEDD remained unchanged: 57.3  8.6 mm preoperatively
1360 The Journal of Thoracic and Cardiovascular Surend-diastolic diameter remained unchanged (P ¼ .291):
57.3  8.6 mm (range, 47-80 mm) preoperatively versus
55.6  8.6 mm (range, 35-73 mm) postoperatively.
Late Survival
The survival in group I at 1, 3, 6, 12, 18, and 24 months
was 95%  5%, 81%  9%, 76%  9%, 76%  9%,
62%  12%, and 62%  12%, respectively. The survival
in the control group II at 1, 3, 6, 12, 18, and 24 months was
95% 1%, 89% 2%, 85% 3%, 82% 3%, 78%
4%, and 62%  7%, respectively. There were no statisti-
cally significant differences between the 2 groups
(P ¼ .207). The Kaplan-Meier survival function is given
in Figure 4. An LVEF of 25% or lower per se was not found
to be a significant predictor for midterm survival in the uni-
variate analysis (P ¼ .206).
DISCUSSION
Favorable Outcome
Our experience with 21 patients with poor left ventricular
performance shows that transapical aortic valve implantationter (LVEDD) in 21 patients with poor left ventricular performance (LVEF
improved significantly up to 2 weeks after TAVI from 20.4%  5.3% to
and 55.6  8.6 mm postoperatively.
gery c June 2012
FIGURE 4. The Kaplan-Meier survival function for 21 patients with a left ventricular ejection fraction (LVEF) between 10% and 25% (solid line) and for
237 patients with an LVEF above 25% (dotted line).
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these critical circumstances. The early results with a 30-
day mortality of 4.8% as well as the midterm outcome
were excellent. We observed a fast improvement in hemody-
namics and left ventricular performance. These results
represent a continuation of our excellent early results
already achieved during our learning curve.15 Furthermore,
they have exceeded our expectations in this cohort of
patients with a true high risk for conventional aortic valve
replacement. In comparison with other therapeutic strate-
gies—that is, only medical management or balloon valvulo-
plasty6—much better results were achieved. Transapical
aortic valve implantation has become de facto our
institutional primary choice of treatment in those patients.Prolonged Recovery
On the other hand, the postoperative course was pro-
longed, especially in patients who had decompensated heart
failure and profound shock. The stay on the intensive care
unit was especially prolonged and respiratory complica-
tions occurred more often. Almost all complications were
related to the preoperative decompensated stage and im-
paired function of other organs. One may conclude from
this that patients should be treated early and electively
rather than on an emergency basis or in the chronic stage
of congestive heart failure. Vice versa, despite the technical
aspects of implantation, success by transapical aortic valve
implantation can be achieved only if there is a highly spe-
cialized team on the intensive care unit taking care of this
specific group of patients 24 hours a day. Respiratory ther-
apists on the intensive care unit are another prerequisite for
successful weaning from the respirator and to prevent theThe Journal of Thoracic and Caroccurrence of associated pneumonia. Furthermore, the pro-
longed stay on the intensive care unit was for safety reasons;
some patients were transferred arbitrarily a few days later
than other patients to the normal ward, although recompen-
sation had already been achieved.Role of CPB
CPB is rarely necessary for transcatheter aortic valve im-
plantation, but it is a prerequisite for the procedure to have
the heart–lung machine ready to use in the operating room
and it is an important part of the safety net.19 Furthermore,
its elective use may increase the safety in critically ill pa-
tients, especially during the learning curve.15 We consider
the use of the heart–lung machine in the following 3
ways: (1) placement of the connecting tubes on the table,
(2) cannulation of the femoral vessels without starting up
the heart–lung machine, and (3) valvuloplasty and valve de-
ployment under a short duration of CPB. The first strategy
may save time if complications occur. We use it, for in-
stance, in patients with a small distance of the coronary os-
tia to the aortic annulus or in patients with severe pulmonary
hypertension. The second strategy seems to be justified in
patients with markedly reduced left ventricular function
(ie, LVEF<25%) or severe regurgitation of the atrioven-
tricular valves. If hemodynamic instability (refractory to
high-dose catecholamine application) occurs, the heart–
lung machine may be started within 1 second after simply
removing the clamps on the connecting tubes. The third
strategy is considered at our institution in patients with
poor left ventricular performance (LVEF 10%-20%), in
the presence of cardiogenic shock, and in patients with de-
compensated right-sided heart failure with enlarged rightdiovascular Surgery c Volume 143, Number 6 1361
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fibrillation is often difficult to manage. Primary use of
CPB instead of its secondary use on an emergency basis
provides superior results. On the other hand, transapical
aortic valve implantation with the safety of the heart–lung
machine is a very simple way to eliminate aortic valve ste-
nosis in these critically ill patients. From our initial experi-
ence, it seems to provide much better early results in
comparison with conventional aortic valve replacement,
which carries a relatively high operative mortality in these
specific patients.3
Myocardial Recovery
A poor LVEF of 25% or below immediately before the
procedure was not associated with a poorer prognosis. De-
spite a longer recovery period in patients with an LVEF of
10% to 25%, midterm outcome did not differ from that
of patients with an LVEF higher than 25%. We observed
a 1-year survival of 76% (LVEF  25%) and 82%
(LVEF>25%) and a 2-year survival of 62% in both sub-
groups. This emphasizes that in these polymorbid and
mostly elderly patients, life-expectancy in the midterm
follow-up is limited even after complete elimination of aor-
tic valve stenosis and is further determined by other diseases
regardless of the ejection fraction in the decompensated
stage preoperatively.
LVEF increased from 20% to 38%. If there was a myo-
cardial contractility reserve, left ventricular performance
was restored quickly after elimination of aortic valve steno-
sis. Transapical aortic valve implantation in these very
high-risk patients can be performed safely when the whole
repertoire of cardiac surgery is applied, including the use of
the heart–lung machine in some of these specific cases. The
use of intra-aortic balloon counterpulsation may support
myocardial recovery.We consider its elective use in patients
with cardiogenic shock and significant catecholamine
support after valve implantation. We observed a lower
LVEF in preoperative transesophageal echocardiography
compared with transthoracic echocardiography a few days
before the procedure in some patients. Since decompensa-
tion is an ongoing process, estimation of left ventricular
performance by transesophageal echocardiography imme-
diately before the procedure is mandatory in our experience.
CONCLUSIONS
This study confirms in a cohort of 21 patients that trans-
apical aortic valve implantation is a feasible method to treat
patients with poor left ventricular performance, advanced
heart failure, or cardiogenic shock. The advantage of the hy-
brid procedure is its lesser invasiveness compared with con-
ventional surgery that carries the additional myocardial
trauma of cardioplegic cardiac arrest. If the excellent early
results are confirmed in a larger group of patients, this
method may become the standard therapy to treat aortic1362 The Journal of Thoracic and Cardiovascular Survalve stenosis in the presence of decompensated heart fail-
ure. Indeed, transapical aortic valve implantation was much
more than an ultima-ratio attempt in our patients who had
a high risk for conventional aortic valve replacement.
A major limitation of the present study is the limited
number of patients and a relatively short follow-up interval.
A close follow-up is necessary for each of them. Beside fur-
ther close observations of clinical signs of heart failure, the
left ventricular performance needs to be evaluated by echo-
cardiography in the longer follow-up.
Other members of the TAVI team are Dr Alexander Mladenow,
Dr Christoph Klein, and Katrin Sch€afer. We thank Anne Gale for
editorial assistance and Julia Stein for statistical analyses.
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